Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Inclusion Criteria: * Male or female participants ≥18 years of age at the time of signing the informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participant must have one of the following that has progressed or was non-responsive to prior systemic therapy and for which no standard or available known therapeutic option exists: 1. locally advanced or metastatic epithelial ovarian cancer (including fallopian tube or primary peritoneal), or 2. metastatic breast cancer, or 3. metastatic castration-resistant prostate cancer (mCRPC), or 4. pancreatic adenocarcinoma * Measurable disease per RECIST v1.1 (exceptions for participants with non-measurable but evaluable disease \[per RECIST and or PSA/CA-125\]) * Next generation sequencing (NGS) report demonstrating eligible tumor biomarker * Provision of archival tumor tissue, or if adequate archival tumor tissue is not available, provision of a fresh biopsy if there is a lesion that can be safely biopsied * Acceptable organ function at Screening * Acceptable hematologic function at Screening * Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment Exclusion Criteria: * History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment. * Uncontrolled, symptomatic brain metastases. * Presence of other known active invasive cancers * History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis * Prior therapy with a Polθ inhibitor other than RP-3467